JP7777874B2 - 免疫調節機能を有するＣｐＧ ＯＤＮ及びその使用 - Google Patents

免疫調節機能を有するＣｐＧ ＯＤＮ及びその使用

Info

Publication number
JP7777874B2
JP7777874B2 JP2022559536A JP2022559536A JP7777874B2 JP 7777874 B2 JP7777874 B2 JP 7777874B2 JP 2022559536 A JP2022559536 A JP 2022559536A JP 2022559536 A JP2022559536 A JP 2022559536A JP 7777874 B2 JP7777874 B2 JP 7777874B2
Authority
JP
Japan
Prior art keywords
vaccine
cpg odn
immunomodulatory
cells
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519413A (ja
JP2023519413A5 (https=
Inventor
ワン，リーゴン
シャオ，ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parr Biotechnology Hebei Co Ltd
Original Assignee
Parr Biotechnology Hebei Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parr Biotechnology Hebei Co Ltd filed Critical Parr Biotechnology Hebei Co Ltd
Publication of JP2023519413A publication Critical patent/JP2023519413A/ja
Publication of JP2023519413A5 publication Critical patent/JP2023519413A5/ja
Application granted granted Critical
Publication of JP7777874B2 publication Critical patent/JP7777874B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022559536A 2020-04-01 2021-03-31 免疫調節機能を有するＣｐＧ ＯＤＮ及びその使用 Active JP7777874B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010253089.8A CN113493790A (zh) 2020-04-01 2020-04-01 具有免疫调节功能的CpG ODN及其应用
CN202010253089.8 2020-04-01
PCT/CN2021/084467 WO2021197381A1 (zh) 2020-04-01 2021-03-31 具有免疫调节功能的CpG ODN及其应用

Publications (3)

Publication Number Publication Date
JP2023519413A JP2023519413A (ja) 2023-05-10
JP2023519413A5 JP2023519413A5 (https=) 2024-04-10
JP7777874B2 true JP7777874B2 (ja) 2025-12-01

Family

ID=77929639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559536A Active JP7777874B2 (ja) 2020-04-01 2021-03-31 免疫調節機能を有するＣｐＧ ＯＤＮ及びその使用

Country Status (5)

Country Link
US (1) US12600973B2 (https=)
EP (1) EP4130268A4 (https=)
JP (1) JP7777874B2 (https=)
CN (2) CN113493790A (https=)
WO (1) WO2021197381A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115252772A (zh) * 2021-04-30 2022-11-01 华普生物技术(江苏)股份有限公司 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN116064548B (zh) * 2022-12-01 2023-07-28 北京吉诺卫生物科技有限公司 一种新型CpG疫苗佐剂及其应用
CN118356486A (zh) * 2023-01-19 2024-07-19 华普生物技术(河北)股份有限公司 CpG佐剂在制备新型冠状病毒疫苗中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005476A2 (en) 2002-07-03 2004-01-15 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2005060377A2 (en) 2003-12-08 2005-07-07 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
WO2019115385A1 (en) 2017-12-15 2019-06-20 Bayer Animal Health Gmbh Immunostimulatory compositions
JP2019163302A (ja) 2019-05-23 2019-09-26 国立研究開発法人医薬基盤・健康・栄養研究所 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
JP2019172701A (ja) 2014-01-21 2019-10-10 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖体およびそれらのコンジュゲート

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1271733A (zh) * 2000-04-04 2000-11-01 中国预防医学科学院病毒学研究所 对人免疫细胞有特异免疫刺激活性的CpG寡核酸
US7491706B2 (en) * 2003-07-25 2009-02-17 Changchun Huapu Biotechnology Co., Ltd. Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof
CN101492672B (zh) 2008-01-23 2011-01-26 许洪林 具有免疫刺激活性的硫代寡聚脱氧核苷酸及其应用
CN105214083A (zh) * 2014-06-26 2016-01-06 长春华普生物技术有限公司 含有CpG寡核苷酸的药物组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005476A2 (en) 2002-07-03 2004-01-15 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2005060377A2 (en) 2003-12-08 2005-07-07 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
JP2019172701A (ja) 2014-01-21 2019-10-10 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖体およびそれらのコンジュゲート
WO2019115385A1 (en) 2017-12-15 2019-06-20 Bayer Animal Health Gmbh Immunostimulatory compositions
JP2019163302A (ja) 2019-05-23 2019-09-26 国立研究開発法人医薬基盤・健康・栄養研究所 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用

Also Published As

Publication number Publication date
CN113493790A (zh) 2021-10-12
JP2023519413A (ja) 2023-05-10
WO2021197381A1 (zh) 2021-10-07
US20230159936A1 (en) 2023-05-25
EP4130268A1 (en) 2023-02-08
CN115413298A (zh) 2022-11-29
EP4130268A4 (en) 2024-10-02
US12600973B2 (en) 2026-04-14

Similar Documents

Publication Publication Date Title
Uhlmann et al. Recent advances in the development of immunostimulatory oligonucleotides
JP7777874B2 (ja) 免疫調節機能を有するＣｐＧ ＯＤＮ及びその使用
Mutwiri et al. Biological activity of immunostimulatory CpG DNA motifs in domestic animals
Warshakoon et al. Potential adjuvantic properties of innate immune stimuli
EP0855184A1 (en) Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
AU2010213795A1 (en) Synthetic RNA-based agonists of TLR7
US9260719B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US12569553B2 (en) Shingles vaccines comprising a TLR9 agonist
US20230218740A1 (en) Coronavirus vaccines comprising a tlr9 agonist
Chaung CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy
EP1165773A1 (en) Advanced antigen presentation platform
EP1657307A1 (en) Oligonucleotides that induce the secretion of GM-CSF
Tassakka et al. Current research on the immunostimulatory effects of CpG oligodeoxynucleotides in fish
CN110218729B (zh) 一种鸡特异性免疫活化剂CpG-ODN及其应用
Dar et al. Immunotherapeutic potential of CpG oligonucleotides in chickens
US20070082863A1 (en) Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds
Domeika Porcine immunoregulatory cytokines
Ausín Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs
JP2013510189A (ja) 非ｄｎａ塩基含有ポリヌクレオチド組成物、および免疫応答の調節のためのそれらの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251111

R150 Certificate of patent or registration of utility model

Ref document number: 7777874

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150